作者
Jennifer Hannah,Mia Rodziewicz,Puja Mehta,Kerri-Marie Heenan,E. Ball,Shaney Barratt,Sara Carty,Richard Conway,Caroline Cotton,Sarah J. Cox,Anjali Crawshaw,Julie Dawson,Sujal R. Desai,Ahmed Fahim,Carol Fielding,Mark Garton,Peter M. George,Harsha Gunawardena,Clive Kelly,Fasihul Khan,Gouri Koduri,Helen Morris,Marium Naqvi,Elizabeth Perry,Claire Riddell,C. Sieiro Santos,Lisa Spencer,Nazia Chaudhuri,Muhammad K Nisar
摘要
Abstract Interstitial lung disease (ILD) is a significant complication of many systemic autoimmune rheumatic diseases (SARDs), although the clinical presentation, severity and outlook may vary widely between individuals. Despite the prevalence, there are no specific guidelines addressing the issue of screening, diagnosis and management of ILD across this diverse group. Guidelines from the ACR and EULAR are expected, but there is a need for UK-specific guidelines that consider the framework of the UK National Health Service, local licensing and funding strategies. This article outlines the intended scope for the British Society for Rheumatology guideline on the diagnosis and management of SARD-ILD developed by the guideline working group. It specifically identifies the SARDs for consideration, alongside the overarching principles for which systematic review will be conducted. Expert consensus will be produced based on the most up-to-date available evidence for inclusion within the final guideline. Key issues to be addressed include recommendations for screening of ILD, identifying the methodology and frequency of monitoring and pharmacological and non-pharmacological management. The guideline will be developed according to methods and processes outlined in Creating Clinical Guidelines: British Society for Rheumatology Protocol version 5.1.